Company Encyclopedia
View More
name
Nkarta
NKTX.US
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc.
1.946 T
NKTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nkarta to Join Evercore Healthcare Conference in Miami

    Nkarta Inc. will join the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025, featuring a fireside chat at 10:50 a.m. ET. A live webcast and replay will be available on Nkarta's website for 90 days. This news was generated by AI and is for informational purposes only.

    Reuters·
    US
    NKTX
    +3.37%
    Reuters·
    US
    NKTX
    +3.37%

    FY2025 EPS Estimates for Nkarta Increased by Leerink Partnrs

    Leerink Partners increased Nkarta's FY2025 EPS estimate from ($1.48) to ($1.41). Analysts have mixed ratings: four Buy, one Hold, one Sell. Nkarta's stock opened at $1.96, with a market cap of $139.22 million. Hedge funds own 80.54% of the stock. Nkarta develops CAR NK therapies for cancer and autoimmune diseases, with NKX019 in Phase 1 trials.

    Market Beat·
    US
    NKTX
    +3.37%
    Market Beat·
    US
    NKTX
    +3.37%

    FY2025 Earnings Estimate for Nkarta Issued By William Blair

    William Blair raised Nkarta's FY2025 EPS estimate to ($1.36) from ($1.38). The consensus full-year EPS is ($1.70). FY2026 EPS is estimated at ($1.29). Nkarta's stock has a Moderate Buy rating with a consensus target price of $13.25. Institutional investors hold 80.54% of the stock. Nkarta develops CAR NK therapies for cancer and autoimmune diseases.

    Market Beat·
    US
    NKTX
    +3.37%
    Market Beat·
    US
    NKTX
    +3.37%

    Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price

    Needham analyst Gil Blum has maintained a Buy rating on Nkarta with a target price of $10. This rating is based on Nkarta's strategic management and strong financial position, including cash reserves of $316.5 million. The company has delayed the results of its Ntrust-1/2 trials to 2026 for more comprehensive data, while recent FDA interactions have streamlined the trial process. These factors contribute to the positive outlook for Nkarta, as Blum focuses on the Healthcare sector with a notable success rate.

    Tip Ranks·
    US
    NKTX
    +3.37%
    Tip Ranks·
    US
    NKTX
    +3.37%

    Nkarta | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    NKTX
    +3.37%
    LB filings·
    US
    NKTX
    +3.37%
    © 2025 Longbridge｜Disclaimer